<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> level is usually used to diagnose <z:mp ids='MP_0002055'>diabetes</z:mp>, but is not a good predictor of postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, which is a more accurate measure of the metabolic defect underlying type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels may be elevated while fasting levels are <z:mpath ids='MPATH_458'>normal</z:mpath>, constituting an early stage in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> that can be termed 'postprandial <z:mp ids='MP_0002055'>diabetes</z:mp>' </plain></SENT>
<SENT sid="2" pm="."><plain>Prevention of postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is important, as it is implicated in the development of macro- and microvascular complications associated with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> is higher in individuals with postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, even without <z:mp ids='MP_0002055'>diabetes</z:mp>, than in individuals with <z:mpath ids='MPATH_458'>normal</z:mpath> postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is implicated in the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Even modest postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> may lead to <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Agents that reduce postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> have a key role in the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">pre-diabetic</z:e> states </plain></SENT>
<SENT sid="7" pm="."><plain>Most anti-diabetic agents that are currently available reduce fasting blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, but have little impact on postprandial glycaemic excursions and thus do not normalize postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>However, new agents that control postprandial <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> have been developed, for example, the alpha-glucosidase inhibitor <z:chebi fb="0" ids="2376">acarbose</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>Such agents have a potential to reduce the progression of <z:mp ids='MP_0002055'>diabetes</z:mp> as well as macro- and microvascular complications </plain></SENT>
</text></document>